The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version.

By Bin Zhao, Li Li, Q. Lei, K. Guan. Genes & Development, 2010

1,167 citations recorded by the source corpus.

The Hippo signaling pathway is gaining recognition as an important player in both organ size control and tumorigenesis, which are physiological and pathological processes that share common cellular signaling mechanisms. Upon activation by stimuli such as high cell density in cell culture, the Hippo pathway kinase cascade phosphorylates and inhibits the Yes-associated protein (YAP)/TAZ transcription coactivators representing the major signaling output of the pathway. Altered gene expression resulting from YAP/TAZ inhibition affects cell number by repressing cell proliferation and promoting apoptosis, thereby limiting organ size. Recent studies have provided new insights into the Hippo signaling pathway, elucidating novel phosphorylation-dependent and independent mechanisms of YAP/Yki inhibition by the Hippo pathway, new Hippo pathway components, novel YAP target transcription factors and target genes, and the three-dimensional structure of the YAP-TEAD complex, and providing further evidence for the involvement of YAP and the Hippo pathway in tumorigenesis.

Subfields: Cell Biology

View Paper: https://www.semanticscholar.org/paper/12871f8dad4642ee45e6a6f8612de2382e70e7d3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. K. Guan
2. Fa-Xing Yu
3. S. Piccolo
4. Bin Zhao
5. M. Cordenonsi
6. S. Dupont
7. Duojia Pan
8. K. Tumaneng

Citations in the corpus

• The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain (2012, background): “The members of the transcriptional enhancer factor/TEA domain (TEF/TEAD) family of transcription factors are major mediators of YAP transcriptional activity (6, 7).”
• Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. (2011, background): “In the last decade, the Yes-associated protein (YAP) transcription coactivator was shown to play an important role in organ size homeostasis, and was demonstrated to be inhibited by the Hippo signaling pathway (for review, see Zhao et al. 2010a).”
• Force Triggers YAP Nuclear Entry by Regulating Transport across Nuclear Pores. (2017, positive): “Yes-associated protein (YAP) is a mechanosensitive transcriptional regulator with a major role in cancer and other diseases (Moroishi et al., 2015; Plouffe et al., 2015; Zanconato et al., 2016), development (Porazinski et al., 2015; Varelas, 2014), and organ size control (Zhao et al., 2010).”
• Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. (2012, background): “Keywords Hippo signaling YAP chemical biology oncogene The Hippo tumor suppressor pathway restricts organ size in Drosophila and mammals by antagonizing the oncoprotein Yki/YAP (Zeng and Hong 2008; Pan 2010; Zhao et al. 2010; Halder and Johnson 2011).”
• Regulation of the Hippo-YAP pathway by G-protein coupled receptor signaling (2012, background): “Genetically modified mouse models demonstrate that 780 Cell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc. function of the Hippo pathway in organ size regulation is conserved in mammals (reviewed in Zhao et al., 2010a).”
• The biology of YAP/TAZ: hippo signaling and beyond. (2014, background): “LATS1/2 phosphorylate YAP at five serine/threonine residues (defined by the consensus HxRxxS), and TAZ has four of these sites (262) (FIGURE 1).”
• The Hippo pathway: regulators and regulations. (2013, background): “YAP/TAZ in conjunction with TEAD1–4 (Sd orthologs) mediate major physiological functions of the Hippo pathway (Fig. 2; for reviews, see Pan 2010; Zhao et al. 2010a).”